Italy Pharmaceuticals & Healthcare Report Q1 2008

  • ID: 591698
  • February 2008
  • Region: Italy
  • 63 pages
  • Business Monitor International
1 of 4


  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Recordati
  • Sanofi-Aventis
  • MORE

The Italy Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Italys pharmaceuticals and healthcare industry.

Sales in Italy’s retail pharmacy sector are continuing to fall due to the impact of price cuts enacted in 2006. However, overall growth should be reasonable over the forecast period, clocking in at around 4.3% per annum. The author believes much of the growth will be driven by the consumer health sector, which is benefiting from the impact of liberalisation. Meanwhile, the generics sector is experiencing exceptional growth, albeit form a small base, and should account for almost 10% of the market by 2012.

However, belt-tightening from the current administration looks set to continue in 2008, as Italy attempts to reduce its sizeable national debt. This could trigger further austerities in the health and drug sectors, even though the country has been rocked by three strikes from medical workers in the past two years.

This propensity for industrial action might force the government to think carefully before implementing any deep cuts. Meanwhile, the current policy of high taxation and low public spending READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Recordati
  • Sanofi-Aventis
  • MORE

Executive Summary 5
Table: Italy Pharmaceuticals And Healthcare Industry SW 6
Italy Political SWOT 6
Italy Economic SWOT 7
Pharmaceutical Business Environment Ratings 8
Pharmaceutical Ratings - Revised Methodology 8
Ratings Overview 8
Table: Pharmaceutical Business Environment Indicators 9
Weighting 10
Table: Weighting Of Components 10
Italy -Business Enviroment Rating 11
Table: Business Environment Rankings 11
Limits To Potential Returns 11
Risks To Realisation Of Returns 12
Western Europe Overview 13
Market Summary 14
Healthcare Sector15
Regulatory Regime17
Intellectual Property Developments 17
Pricing And Reimbursement Issues 18
Industry Developments 21
Company Developments 23
Eye On Recordati 24
Growth Continues At Chiesi 28
Rottapharm Makes A Splash 29
Table: Rottapharm Timeline 29
Biotechnology 30
Clinical Trials 31
Over-The-Counter Sector 32
Pharmacy Sector 32
Industry Forecast Sce34
Overall Market Forecast 34
Table: Drug Market Indicators 35
Key Growth Factors - Industry 36
Table: Health Expenditure Indicators 37
Key Growth Factors - Macroeconomic 38
Table: Italy - Macroeconomic Forecasts 40
Prescription Market Forecast 41
Table: Prescription Drug Market Indicators (US$mn unless otherwise stated) 42
OTC Market Forecast 43
Table: OTC Market Indicators (US$mn unless otherwise stated) 44
Generic Market Forecast 45
Table: Generics And Branded Market Indicators 46
External Trade Forecast 47
Table: Pharma Trade Indicators (US$mn) 49
Other Healthcare Data Forecasts 49
Table: Socio-Demographic Indicators 49
Competitive Landscape50
Company Profiles51
Leading Multinational Manufacturers 51
GlaxoSmithKline 51
Pfizer 53
Novartis 54
Sanofi-Aventis 56
Merck & Co 57
Indigenous Manufacturer 58
Recordati 58
Our Forecast Modelling 61
How We Generate Our Industry Forecasts 61
Pharmaceutical Industry 62
Sources 62

Note: Product cover images may vary from those shown
3 of 4

- GlaxoSmithKline
- Merck & Co
- Novartis
- Pfizer
- Recordati
- Sanofi-Aventis

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown





Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S